COMMUNIQUÉS West-GlobeNewswire
-
Addgene Appoints Greg Crescenzi as Vice President of Global Commercial Strategy and Partnerships
26/02/2026 -
Cannara annonce son entrée à la Bourse de Toronto
26/02/2026 -
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
26/02/2026 -
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
26/02/2026 -
Highridge Medical Begins a Limited Launch of the activL® Lumbar Disc with Strong Early Surgeon Adoption
26/02/2026 -
The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month
26/02/2026 -
Glow Holdings, Inc. Launches New Corporate Website
26/02/2026 -
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026 -
New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
26/02/2026 -
Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
26/02/2026 -
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026 -
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
26/02/2026 -
ImageneBio to Participate in Leerink Global Healthcare Conference
26/02/2026 -
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026 -
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
26/02/2026 -
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
26/02/2026 -
Cannara Announces Graduation to the Toronto Stock Exchange
26/02/2026 -
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02/2026 -
Iovance Biotherapeutics to Present at Upcoming Conferences
26/02/2026
Pages